RSV Seasonal Vaccine Introduction and Growth Strategy

Continued strong commercial execution Q2 2023 growth across all product areas and all regions Sales contribution by product area¹ Sales contributions by region1 Sales (£m) Vaccines 8,000 7,000 6,000 5,000 4,000 3,000 2,000 1,000 GSK Specialty Medicines Q2 2022 General Medicines US Europe International 8,000 Absolute values at AER; changes at CER, unless stated otherwise 1. Excluding COVID-19 solutions +8% +12% Sales (£m) 7,000 6,000 5,000 +17% +12% 4,000 3,000 2,000 +15% 1,000 Q2 2023 +8% 0 Q2 2022 Q2 2023 15

View entire presentation